anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The investigators will enroll 30 patients with PD, randomly divided into two groups: (A) gait training with Music; (B) conventional treadmill gait training. The 15 patients in the experimental group will perform training by means of the device Gait Trainer 3 (Biodex), where they will train on a tredmill equipped with music. They will walk following specific musical beets and rhythms so to entrain their own internal rhythm. Subjects will attend 3 sessions a week for at least 4 weeks. Each session will last 45-min.
Two 50-minute sessions per week. Each weekly fPT session consists of 50 minutes of active treatment, a 'dose' equivalent to time spent in active treatment in the LOK arm. Techniques that focus on body structure changes will be not be permitted (e.g., inhibitive casting, kinesiotaping, functional electrical stimulation).
The disclosed systems and methods manage more notifications between medical devices. A method includes obtaining information corresponding to a clinician and determining whether the information satisfies coordination criteria. The method includes, in accordance with a determination that the clinician is associated with the first medical device and a second medical device, detecting a first and second notification generated by respective medical devices. The method includes identifying, based on detecting the respective notifications, alert information including medical information for a patient receiving medical treatment from the first and second medical device. The method includes determining, based on the identified information, notification priorities between the respective notifications. The method includes adjusting at least one human perceivable manifestation of the respective notifications based on the determined notification priorities, and presenting adjusted human perceivable manifestations of the respective notifications to the user via one of the first medical device or the second medical device.
A modular surgical system for use in a surgical procedure is disclosed. The modular surgical system includes: a control module including a power source; and a surgical module including a first surgical module and a second surgical module. The first surgical module is arranged with the control module and the second surgical module in a stacked configuration. The power source is configured to output power to the first surgical module and the second surgical module. The power backplane is configured to deliver power to the first surgical module and through the first surgical module to the second surgical module. The control circuit is configured to adaptively adjust the power distribution to the first surgical module and the second surgical module.
Participants will receive polatuzumab vedotin 1.8 milligrams per kilogram (mg/kg) intravenously (IV), placebo for vincristine IV, rituximab 375 milligrams per square meter (mg/m\^2) IV, cyclophosphamide 750 mg/m\^2 IV, and doxorubicin 50 mg/m\^2 IV on Day 1 and prednisone 100 milligrams per day (mg/day) orally (PO) on Days 1-5 of every 21-day cycle for 6 cycles. Rituximab 375 mg/m\^2 IV will be administered as monotherapy in Cycles 7 and 8.
Kidney stones, a prevalent urological disorder, are closely associated with oxidative stress (OS) and the inflammatory response. Recent research in the field of kidney stone treatment has indicated the potential of natural active ingredients to modulate OS targets and the inflammatory response in kidney stones. Oxidative stress can occur through various pathways, increasing the risk of stone formation, while the inflammatory response generated during kidney stone formation further exacerbates OS, forming a detrimental cycle. Both antioxidant systems related to OS and inflammatory mediators associated with inflammation play roles in the pathogenesis of kidney stones. Natural active ingredients, abundant in resources and possessing antioxidative and anti-inflammatory properties, have the ability to decrease the risk of stone formation and improve prognosis by reducing OS and suppressing pro-inflammatory cytokine expression or pathways. Currently, numerous developed natural active ingredients have been clinically applied and demonstrated satisfactory therapeutic efficacy. This review aims to provide novel insights into OS and inflammation targets in kidney stones as well as summarize research progress on potential therapeutic strategies involving natural active ingredients. Future studies should delve deeper into exploring efficacy and mechanisms of action of diverse natural active ingredients, proposing innovative treatment strategies for kidney stones, and continuously uncovering their potential applications.
This is a double blind randomized study with two parallel groups. Children between 3 and 15 years of age with indication of laparoscopic appendectomy will be approached for inclusion in this trial. Informed consent will be asked for from the parents and the child. Before surgery, patients will be randomized to either local infiltration of the trocar wounds or TAP block using sequentially numbered sealed envelope each with a random number inside. Patients with peritonitis will be excluded. A standardized analgesia protocol within the first 24 post-operative hours will be applied and the primary outcome is nalbuphine consumption during this time frame. Secondary outcomes include postoperative pain (FLACC assessment tool) and postoperative nausea and vomiting.
FIELD: medicine. ^ SUBSTANCE: invention relates to medicine, namely to creation of medicinal composition in form of gel for external application, which has anti-inflammatory and antiallergic effect. Gel includes as active substance Xymedon, as antihistamine preparation - diphenhydramine, or clemastine, or cetirizine, gel base with thickener carbopol, polyethylene oxide with molecular weight 400-6000 Da and purified water. Gel also can contain glycerin, ethanol, menthol, preservative - nipagin or benzalkonium chloride, stabiliser and neutralising agent. ^ EFFECT: gel is characterised by high therapeutic activity in treatment of skin diseases, vasomotor and allergic rhinitis, inflammatory diseases of eyes with allergic manifestations. ^ 5 cl, 2 tbl, 29 ex
Participants will be randomised to receive remote ischaemic conditioning (RIC) with exercise involving a 4-week home-based programme of RIC with exercise . The exercise will involve handgrip exercise during the cuff deflation phase of RIC.
To assess outcomes of supracostal ultrasound guided approach percutaneous nephrolithotomy (SUGA-PNL) and retrograde intrarenal surgery (RIRS) in isolated large volume upper calyceal stones (UCS). This was a prospective randomized study including patients with isolated UCS > 20mm. The patients were randomized into two groups: group (P) (SUGA-PNL) and group (R) (RIRS). Patients' demographics, stones characteristics, operative, and postoperative outcomes essentially the stone free rate (SFR) and complications rate were documented. The stone clearance was defined as no fragments or residual fragments less than 2mm in the one month non contrast CT scan follow up. Eighty-nine patients opted to undergo the procedure according to the preoperative randomization. Four patients, 2 patients from each group, lost to follow up and other 2 patients were excluded from group (R) due to a tight ureter. Both groups were comparable as regards the preoperative demographics and stone characteristics. There were statistically significant differences regarding total operative time, the change in hemoglobin level, and postoperative pain score (P: 0.024, 0.010 and 0.032 respectively). The SFR was 88.1% in group (P) compared to 73.2% in group (R) (P: 0.019). Moreover, it did not differ significantly between both groups regarding the intraoperative and postoperative complications. No visceral and thoracic injuries were documented in group (P). On other side, 6 patients (14.6%) from group (R) had different grades of ureteral injury during access sheath placement. SUGA-PNL is a safe and effective treatment modality for UCS > 20mm with a higher SFR than RIRS.
Male or female idiopathic pulmonary fibrosis (IPF) sufferers over the age of 40, with a confirmed diagnosis of IPF against international guidelines. Patients are devoid of significant other medical, surgical or psychiatric illnesses that may affect respiratory symptoms or disease progression.
All patients will undergo T-cell collection and CAR T manufacturing as per standard of care. Patients will receive cyclophosphamide per standard of care Day -5 to Day -3. They will subsequently receive TBI on Day -1 then and will receive cilta-cel infusion on Day 0.
The ENTRUST intervention is adaptive based on participant's substance use, HIV status and economic status. Participants in both arms will receive an adapted tailored screening, brief intervention and referral to treatment intervention for transgender women (SBIRT-T) to set personal goals around linking to substance use services, HIV care and linking to financial institutions. As indicated participants may also receive support with mental health services, housing and legal services. Any participant who receives the ENTRUST intervention will also participate in group-based economic empowerment and skill building training, and photovoice training. Photovoice is a process where participants take pictures of their daily lives while they are in the study to help document their experience. The economic empowerment training will be completed using a tailored app developed by the Human Rights Campaign for this Study (WorthIt for ENTRUST) over four sessions. The photovoice training will be facilitated by an ENTRUST facilitator at one of the participating collaborating sites in Orlando or Miami. At the end of the four photovoice sessions, participants may volunteer to do a public exhibit presenting study images from the photovoice activities to key stakeholders to initiate a call to action around policy to impact change that improves transgender women linking to substance use services and HIV care and improving their financial health.
PURPOSE:An immune adjusting agent effective for remedying and preventing malignant tumor, etc., having powerful immune adjusting action, showing low toxicity and safety, containing a compound such as 3-iodo-2-propynyl p-toluenesulfonate, etc. as an active ingredient. CONSTITUTION:An agent containing a compound shown by the formula I (R is triiodovinyl group, iodoethynyl, or ethynyl) as an active ingredient. The compound is used in the same dosage form and by administration method as those of common immune adjusting agent, carcinostatic agent, etc. Properly a daily dosage is usually 0.001-1mg per kg weight in the case of oral administration, and 0.0001-1mg in the case of hypodermic and intramuscular administration. In the synthesis of the active ingredient, a compound shown by the formula III as a raw material obtained from 2-propyne-1-ol shown by the formula II is treated with iodine in the presence of an alkali reagent to give a compound shown by the formula IV among the compound shown by the formula I , which is further reacted with iodine to give a compound shown by the formula V.
New protease-resistant single-chain urokinase derivatives are provided. In particular, derivatives are provided in which the Lys135, Lys136 and Arg156 to Lys158 sites are blocked or modified covalently so as to be less susceptible to proteolytic cleavage. The preferred covalent modifications are variants of the amino acid sequence at the sites where proteolysis of urokinase occurs. These are produced optically by synthesis of single-chain urokinase mutants in recombinant cell culture. The new urokinase derivatives of the present invention offer the advantage of avoiding the substantial generation of double-chain urokinase, either in vivo or during recombinant cell culture. However, the derivatives still activate plasminogen in blood clot lysis initiation.
The invention discloses the application of dioscin to the preparation of a renal injury protection medicament. Dioscin has a renal injury protection effect, and can be used for preparing the renal injury protection medicament. Dioscin has an obvious lowering effect on NO (Nitric Oxide), TNOS (Total Nitric Oxide Synthase), iNOS (Inducible Nitric Oxide Synthase), MDA (Malondialdehyde), BUN (Blood Urea Nitrogen) and SCr (Serum Creatinine) rise caused by renal injury, has an obvious increasing effect on the reduction of SOD (Superoxide Dismutase), GSH (Glutathione), GSH-Px (Glutathione Peroxidase) and CAT (Catalase) relative to a Model group, and is dose-dependent. After the intervention of dioscin, the phenomena of large-area renal tubular epithelial cell swelling, brush border disappearance, degenerative necrosis of a part of epithelial cells, blockage of lumens by necrotic and exfoliative cellular debris and the like, which are caused by renal injury are obviously alleviated. Dioscin can be used for preparing a medicinal preparation as an active ingredient according to clinical medication needs. Dioscin has the advantages of safety (no toxic or side effects), effectivity, economy, practicability and the like.
The Futuros Fuertes 2.0 intervention includes brief health education and coaching at well child visits in the first two years of life that addresses optimal feeding, screen time and sleep practices. In addition, caregivers receive 2 text messages per week. Caregivers also receive environmental prompts to help support healthy behaviors at home.
The early childhood education and care (ECEC) professionals in the intervention arm groups were instructed to use the application with a tablet computer at least 1-2 times a week during the intervention period (3-4 weeks) and to record the number of tasks completed by their group in a logbook. In addition, we recommended that each group focus on at least six vegetables or fruits during the intervention period.
The invention relates to a Tibetan medicine composition, in particular to a Tibetan medicine composition for regulating blood fat and a preparation method of the composition. The composition comprises the following raw materials in parts by weight: 50-150 parts of rheum australe, 40-120 parts of hawthorn and 30-90 parts of emblic leafflower fruit. The preparation method comprises the steps of preparing rheum australe with vinegar, selecting and concentrating raw materials, adding materials, drying, granulating or filtering, filling capsules or filling and the like. The invention uses the special plant materials of Tibet, thus having rich Tibetan flavor. It can reduce blood viscosity, blood plasma viscosity and fibrinogen content, prevent thrombosis, improve blood flow, and is safe and nontoxic. The three medicines are combined and coordinated with each other, have good treatment effect and health care function on patients with hyperlipidemia and people with dyslipidemia, and are safe to take. The invention can be taken as a medicine or a health-care food, and has obvious effect of regulating the blood fat of a human body.
AIMS: Direct oral anticoagulants (DOACs) are increasingly used off-label to treat patients with left ventricular thrombus (LVT). We analysed available meta-data comparing DOACs and vitamin K antagonists (VKAs) for efficacy and safety.
METHODS: We conducted a systematic search and meta-analysis of observational and randomized data comparing DOACs vs. VKAs in patients with LVT. Endpoints of interest were stroke or systemic embolism, thrombus resolution, all-cause death, and a composite bleeding endpoint. Estimates were pooled using a random-effects model meta-analysis, and their robustness was investigated using sensitivity and influential analyses.
RESULTS: We identified 22 articles (18 observational studies, 4 small randomized clinical trials) reporting on a total of 3587 patients (2489 VKA vs. 1098 DOAC therapy). The pooled estimates for stroke or systemic embolism [odds ratio (OR): 0.81; 95% confidence interval (CI): 0.57, 1.15] and thrombus resolution (OR: 1.12; 95% CI: 0.86, 1.46) were comparable, and there was low heterogeneity overall across the included studies. The use of DOACs was associated with lower odds of all-cause death (OR: 0.65; 95% CI: 0.46, 0.92) and a composite bleeding endpoint (OR: 0.67; 95% CI: 0.47, 0.97). A risk of bias was evident particularly for observational reports, with some publication bias suggested in funnel plots.
CONCLUSION: In this comprehensive analysis of mainly observational data, the use of DOACs was not associated with a significant difference in stroke or systemic embolism, or thrombus resolution, compared with VKA therapy. The use of DOACs was associated with a lower rate of all-cause death and fewer bleeding events. Adequately sized randomized clinical trials are needed to confirm these findings, which could allow a wider adoption of DOACs in patients with LVT.
A therapeutic preparation for the treatment of intestinal diseases is produced by growing a viable apathogenic variety of the species of intestinal bacteria Escherichia Coli or Aerobacter aerogenes in contact with a nutrient medium which contains a nitrogen source and a carbon source and processing the culture thus obtained to form a dry preparation, said variety having natural resistance to at least one antibiotic of the tetracycline series at concentrations of tetracycline exceeding 50 micrograms per millilitre and being fully susceptible to chloramphenicol. Preferred organisms are E. coli NRRL B1958 and A. aerogenes NRRL B1959.  In addition, an antibiotic non-resisting strain of E. coli or A. aerogenes may be present.  The medium contains a source of (a) carbon, e.g. dextrin, starch, glycerine, xylose, glucose, laevulose, cellubiose, inosite, inulin, dulcite, sorbite, lactose, maltose or saccherose, (b) nitrogen, e.g. sodium nitrate and (NH,)2SO4, corn steep liquor, yeast autolysate, peptone and soyabean meal, (c) mineral salts, (d) buffers, and (e) growth-promoting substances.  The bacterial cells obtained at the end of the growth period are centrifuged, washed free from residual nutrient medium and suspended in an aqueous solution containing (a) protective substances which are protein containing, e.g. skimmed milk, carbohydrates, e.g. lactose, tragacanth and pectin, (b) growth promoters, e.g. biotin, p-aminobenzoic acid, nicotinic acid amide, aneurin, lactoflavin, Vitamin B12, folic acid and pantothenic acid. The suspension is then freeze dried.  It may be worked up into solid pharmaceutical preparations, e.g. capsules which may also contain chamomile extract.
FIELD: medicine. ^ SUBSTANCE: group of inventions relates to veterinary, in particular to veterinary virology and biotechnology. In accordance with the first version method of producing vaccine against bluetongue of large and small cattle includes preparation of bluetongue virus inoculum, infecting animal cell culture with inoculum, cultivation of cell-virus suspension, separation of virus specific antigen with its further inactivation and preparation of target product. As animal cell culture, "ÆÜ"-21/13 cells are used. Infecting animal cells is carried out with infecting dose 0.001-0.002 tcd5q/cell. Cultivation of cell-virus suspension is carried out at pH 7.2-7.4 and temperature 36.5-37.5C for 48-72 hours until amount of viable cells is 7-10%. After that cell-virus suspension is centrifuged at 2.5-3.5 thousand rev/min. Antifoam agent in final concentration 0.02-0.025% is added to supernatant. After that chlorophorm in final concentration 0.7-0.8% is introduced into cell-virus suspension with constant mixing. Mixing is performed for 1.5-2.0 hours at pH 7.2-7.4 and temperature 36.5-37.5C. Then reaction mixture is incubated for 1.5-2.0 hours at temperature 36.5-37.5C and centrifuged at 8000-9000 rev/min, antigen is separated in form of supernatant. Antigen is concentrated until infectious activity is reached on "ÆÜ"-21/13 cell culture 6.5-7.5 lg tcd50/cmÇè3 and in accordance with the first version of vaccine production adjuvant in final concentration 40-65% is added to antigen, and in accordance with the second version of vaccine production saponin in final concentration 0.0001-0.0005% or aluminium hydroxide or mixture of aluminium hydroxide and saponin taken with weight ratio 1:0.000004-0.0000625, in final concentration 8-25% are added to antigen. During vaccine production necessity to perform labour-intensive operations connected with washing and preparation of a large number of cultivation vessels and repeated box work with each of them is eliminated completely, amount of full-fledged immunogen from the same volume of virus-containing cell suspension increases. ^ EFFECT: vaccine prepared in accordance with invention, possesses great immunogenic potency and, therefore, will protect animals against bluetongue more reliably. ^ 5 cl, 15 ex
Peroxisome proliferator-activated receptor gamma coactivators 1β (PGC1β) is essential in mitochondrial oxidative phosphorylation and alternative macrophages activation. To determine the contribution of PGC1β in obesity induced inflammation, Ppargc1b (PGC1β coding gene) myeloid conditional knockout mice (cKO) were fed with high fat diet (HFD) to examine the following effects. We found that HFD-fed cKO mice gained more fat with increased serum triglyceride (TG), low density lipoprotein (LDL), adiponectin, and leptin. Adipogenesis was stimulated while lipolysis was retarded in HFD-fed cKO mice adipose. Gluconeogenesis, lipogenesis, and fatty acid uptake were provoked while lipolysis was inhibited in HFD-fed cKO liver. Serum alanine transaminase (ALT) level, indicating fatty liver, also increased. Inflammatory cytokine including tumor necrosis factor-α (TNF-α), IL-1β, and IL-6 was elevated in cKO mice, accompanied with glucose intolerant and insulin resistance. Energy expenditure was decreased in HFD-fed cKO mice. Further evidence showed that cKO macrophages were prone to repolarize into M1 inflammatory type in vitro. In addition to mitochondrial biogenesis and oxidative respiration, PGC1β also modulated mitochondrial fission and cytosolic mitochondrial DNA (mtDNA) release, contributing to NLR family pyrin domain containing 3 (Nlrp3) inflammasome priming and activation. Treatment of mitochondrial fission inhibitor abolished the increased mRNA levels of Nlrp3 and IL-1β induced by PGC1β depletion. Nlrp3 knockdown restored the induced IL-1β mRNA expression by PGC1β deficiency. Myeloid PGC1β regulated adipocyte adipogenesis and lipolysis. PGC1β loss-of-function and mtDNA abundance correlated with obesity and diabetes. These observations uncovered the protective role of PGC1β against obesity induced systemic inflammation. Enhancing myeloid PGC1β function may be a potential strategy for the intervention of obesity and related diseases.
PURPOSE: To obtain the highest density under the sintered condition in several times sintering by using conventional equipment and method, by conducting heating to a sintering temperature, sintering and cooling under particular conditions and under protective gas. CONSTITUTION: A formed and compressed artificial tooth is placed, for example, in a graphite box after having been dried in the air (for 5-25 minutes), and is subjected to heat treatment for 5-45 minutes in the temperature range of 100-400 deg.C. Then, it is heated up to 800 deg.C with the average temperature increase of 50-300K/min, and heated from the preheating temperature to sintering temperature T with the average temperature increase of 20-200K/min by using the air or under protective gas. In this case, sintering temperature T is between the T solidus-200 deg.C and T solidus-70 deg.C, and the T solidus is a solidus temperature of a sintered alloy. Under this temperature, the tooth is sintered for 5-45 minutes by using the air or under protective gas, and cooled in the temperature range lower than 900 deg.C under the vacuum of 1-50HPa or under protective gas. In particular, under the vacuum cooling, such sufficiently high density that pairs the porosity of independent pores can be achieved even after several times sintering.